COMP <GO>
SGRY vs ABBV // FORWARD P/E MULTIPLE
Surgery Partners Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SGRY 7
— ABBV 8
▲ FORWARD P/E MULTIPLE LEADER: SGRY
LAST: $23.21 (0.00%) • MKT CAP: $3.04B
forward-pe
22.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGRY VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SGRY | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 29.00% | -19.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.7x | 33.3x | -23.60 | SGRY | /valuation <GO> |
| Free Cash Flow Yield | 6.44% | 3.47% | +2.97 | SGRY | /fcf-yield <GO> |
| Operating Margin | 45.80% | 24.60% | +21.20 | SGRY | /operating-margins <GO> |
| Net Profit Margin | -9.20% | 6.90% | -16.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 6.60% | 8.60% | -2.00 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.67 | 5.33 | -4.66 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | SGRY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | SGRY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 86.2 | 72.8 | +13.38 | SGRY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.15 | -0.16 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 22.0x | 113.1x | -91.10 | SGRY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.04B | $513.86B | -$510.82B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SGRY REV | ABBV REV | SGRY GROSS % | ABBV GROSS % | SGRY FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | $195.6M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | $209.7M | $17.83B |
| FY 2023 | $0 | $54.32B | — | 44.0% | $293.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGRY // BETA 0.99
ABBV // BETA 1.15